Brown Capital Management LLC Avadel Pharmaceuticals PLC Transaction History

Brown Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 08, 2020	SELL	$4.06 - $10.64 $7.43 Million - $19.5 Million	-1,829,886 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $446,210 - $1.03 Million	133,596 Added 7.88%	1,829,886 $13.8 Million
Q3 2019 Nov 13, 2019	BUY	$1.92 - $4.47 $329,975 - $768,223	171,862 Added 11.27%	1,696,290 $7.06 Million
Q2 2019 Aug 13, 2019	BUY	$1.09 - $3.19 $135,618 - $396,902	124,421 Added 8.89%	1,524,428 $4.41 Million
Q1 2019 May 15, 2019	BUY	$1.44 - $3.29 $437,947 - $1 Million	304,130 Added 27.75%	1,400,007 $2.02 Million
Q4 2018 Feb 14, 2019	BUY	$1.74 - $4.66 $149,118 - $399,362	85,700 Added 8.48%	1,095,877 $2.83 Million
Q3 2018 Nov 14, 2018	BUY	$4.08 - $7.14 $209,365 - $366,389	51,315 Added 5.35%	1,010,177 $4.44 Million
Q2 2018 Aug 14, 2018	BUY	$5.89 - $7.78 $271,905 - $359,155	46,164 Added 5.06%	958,862 $5.88 Million
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $186,927 - $323,528	27,652 Added 3.12%	912,698 $6.65 Million
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $64,970 - $91,023	8,091 Added 0.92%	885,046 $7.26 Million
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $7.32 Million - $9.21 Million	876,955	876,955 $9.21 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Brown Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Brown Capital Management LLC with notifications on news.